Trademark: SEQIRUS 1701396
Word
SEQIRUS
Device Descrption:
2 CURVED STRIPES ATOP LTR S
ID
1701396
Trademark Type
Figurative
Status
Registered: Registered/protected
Application Date
18 June 2015
Registration Date
18 June 2015
Renewal Date
18 June 2025
Owner(s)
Service
Davies Collison Cave Pty Ltd
Goods and Services:
Class 1:
Chemical and biological reagents in this class; cell cultures and media in this class; test kits for scientific and laboratory use in this class, being for diagnostic medical purposes; chemical preparations for scientific and/or industrial purposes; diagnostic and testing agents in this class; chemical and biological reagents for non-medical purposes; chemical and biological reagents for industrial use for anti-body screening, blood grouping, and for the typing and detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes; chemical test kits for the detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes for laboratory or research use; chemical preparations for industrial use for anti-body screening, blood grouping, and the typing and detection of specific blood cells
Chemical and biological reagents in this class; cell cultures and media in this class; test kits for scientific and laboratory use in this class, being for diagnostic medical purposes; chemical preparations for scientific and/or industrial purposes; diagnostic and testing agents in this class; chemical and biological reagents for non-medical purposes; chemical and biological reagents for industrial use for anti-body screening, blood grouping, and for the typing and detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes; chemical test kits for the detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes for laboratory or research use; chemical preparations for industrial use for anti-body screening, blood grouping, and the typing and detection of specific blood cells
Class 5:
Pharmaceutical preparations and substances in this class; vaccines; blood products in this class; products derived from blood and products derived from recombinant DNA technology; serums; antibodies; pharmaceutical test kits in this class, being for diagnostic medical purposes; influenza vaccines; adjuvants and antigens; pharmaceutical preparations and substances for the treatment and/or prevention of blood or bleeding disorders; blood products in this class, namely, blood plasma, reagent blood cells; products derived from blood and products derived from recombinant DNA technology, namely, immunoglobulins, human albumin, blood clotting factors, plasma volume expanders, blood proteins for therapeutic use; serums, namely, anti-venoms; medicated serums for the treatment of blood or bleeding disorders; test kits in the class, namely, invitro diagnostic reagent test kits for use in detecting cell mediated immune response; pharmaceutical preparations and substances, namely, Rheysys Factor D Antigen (RhD) reagents for the detection of specific antigens or in blood typing; pharmaceutical preparations, namely, reagent red blood cells used to detect antibodies or Immunoglobulin (IgG) subtypes; pharmaceutical preparations, namely, monoclonal and polyclonal antibodies; pharmaceutical preparations, namely, reagents for medical/clinical use for the typing and detection of specific blood cells, and the detection of relevant compliment components and immunoglobulin subtypes
Pharmaceutical preparations and substances in this class; vaccines; blood products in this class; products derived from blood and products derived from recombinant DNA technology; serums; antibodies; pharmaceutical test kits in this class, being for diagnostic medical purposes; influenza vaccines; adjuvants and antigens; pharmaceutical preparations and substances for the treatment and/or prevention of blood or bleeding disorders; blood products in this class, namely, blood plasma, reagent blood cells; products derived from blood and products derived from recombinant DNA technology, namely, immunoglobulins, human albumin, blood clotting factors, plasma volume expanders, blood proteins for therapeutic use; serums, namely, anti-venoms; medicated serums for the treatment of blood or bleeding disorders; test kits in the class, namely, invitro diagnostic reagent test kits for use in detecting cell mediated immune response; pharmaceutical preparations and substances, namely, Rheysys Factor D Antigen (RhD) reagents for the detection of specific antigens or in blood typing; pharmaceutical preparations, namely, reagent red blood cells used to detect antibodies or Immunoglobulin (IgG) subtypes; pharmaceutical preparations, namely, monoclonal and polyclonal antibodies; pharmaceutical preparations, namely, reagents for medical/clinical use for the typing and detection of specific blood cells, and the detection of relevant compliment components and immunoglobulin subtypes
Class 44:
Medical services; medical information services; health care services; health care information services; patient support services; providing medical information concerning blood products; providing medical information concerning vaccines, anti-venoms and immunohaematology products, namely, diagnostic reagents; patient support services, namely, providing medical information, including patient medical information via an Internet-based database, where patients can enquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community
Medical services; medical information services; health care services; health care information services; patient support services; providing medical information concerning blood products; providing medical information concerning vaccines, anti-venoms and immunohaematology products, namely, diagnostic reagents; patient support services, namely, providing medical information, including patient medical information via an Internet-based database, where patients can enquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community